Vimarsana
Biggest News Aggregation in the World

Page 23 - Britain Eakin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Britain Eakin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Britain Eakin Today - Breaking & Trending Today

New USPTO Head Sets Sights On Diversity, Arthrex Guidelines - Vimarsana News

New USPTO Head Sets Sights On Diversity, Arthrex Guidelines

U.S. Patent and Trademark Office Director Kathi Vidal said Thursday she's had a busy first week steering the agency, which included working on updated guidance for Arthrex reviews and releasing public comments solicited on the so-called article of manufacture requirement for design patents.

Source: law360.com
Google Gets PTAB To Review IP Involved In $5M Amazon Loss - Vimarsana News

Google Gets PTAB To Review IP Involved In $5M Amazon Loss

The Patent Trial and Appeal Board has agreed to review two Vocalife LLC microphone patents, one of which a Texas jury ordered Amazon to pay $5 million for infringing, agreeing with challenger Google LLC that the patents are likely invalid.

Source: law360.com
SG Urges Justices To Skip Flawed Fed. Circ. IP Suit Ruling - Vimarsana News

SG Urges Justices To Skip Flawed Fed. Circ. IP Suit Ruling

The solicitor general has told the U.S. Supreme Court it should not entertain PersonalWeb Technologies' attempt to rein in the Federal Circuit's use of a 114-year-old doctrine that barred the software development company from suing Amazon's customers for patent infringement.

Source: law360.com
Daiichi Hit With $41.8M Verdict In Cancer Drug IP Fight - Vimarsana News

Daiichi Hit With $41.8M Verdict In Cancer Drug IP Fight

A Texas federal jury found on Friday that Daiichi Sankyo Co. Ltd. owes $41.8 million in damages because a breast cancer treatment medication it markets under the brand name Enhertu infringes a Seagen Inc. patent covering the delivery of a drug called Adcetris.

Source: law360.com
PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict - Vimarsana News

PTAB To Review Cancer Antibody IP That Drew $41.8M Verdict

The Patent Trial and Appeal Board has agreed to review a Seagen Inc. antibody patent after the board previously used its discretion to reject two challenges from Daiichi Sankyo Inc. and AstraZeneca while a Texas federal jury on Friday found Daiichi willfully infringed the patent to the tune of $41.8 million.

Source: law360.com